Allergan PLC (NYSE:AGN)‘s stock had its “market perform” rating restated by equities researchers at William Blair in a research report issued on Monday.

Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Allergan PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Credit Suisse Group AG initiated coverage on shares of Allergan PLC in a research report on Monday, July 25th. They issued an “outperform” rating and a $327.00 price target for the company. Vetr downgraded shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 price target for the company. in a research report on Monday, August 8th. Leerink Swann set a $294.00 price target on shares of Allergan PLC and gave the company a “buy” rating in a research report on Monday, August 8th. Finally, Royal Bank Of Canada reduced their price target on shares of Allergan PLC from $300.00 to $279.00 and set an “outperform” rating for the company in a research report on Thursday, November 3rd. Seven research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $289.11.

Analyst Recommendations for Allergan PLC (NYSE:AGN)

Shares of Allergan PLC (NYSE:AGN) traded down 0.45% during mid-day trading on Monday, reaching $192.22. 1,224,595 shares of the company were exchanged. The company has a market capitalization of $72.10 billion, a price-to-earnings ratio of 5.39 and a beta of 1.08. The firm’s 50-day moving average is $212.72 and its 200-day moving average is $233.35. Allergan PLC has a 12 month low of $184.50 and a 12 month high of $322.68.

Allergan PLC (NYSE:AGN) last released its earnings results on Wednesday, November 2nd. The company reported $3.32 EPS for the quarter, missing the consensus estimate of $3.65 by $0.33. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.73 billion. During the same period in the prior year, the company earned $3.48 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities analysts forecast that Allergan PLC will post $13.37 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 28th. Investors of record on Tuesday, February 28th will be issued a dividend of $0.70 per share. This is an increase from Allergan PLC’s previous quarterly dividend of $0.05. This represents a $2.80 annualized dividend and a yield of 1.46%.

TRADEMARK VIOLATION WARNING: “Allergan PLC (AGN) Earns “Market Perform” Rating from William Blair” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/23/allergan-plc-agn-now-covered-by-william-blair.html.

In related news, CFO Maria Teresa Hilado acquired 1,422 shares of the stock in a transaction on Friday, November 11th. The stock was purchased at an average price of $210.64 per share, for a total transaction of $299,530.08. Following the transaction, the chief financial officer now owns 12,659 shares of the company’s stock, valued at approximately $2,666,491.76. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Brent L. Saunders acquired 5,250 shares of the stock in a transaction on Monday, November 21st. The stock was bought at an average price of $189.13 per share, with a total value of $992,932.50. The disclosure for this purchase can be found here. Corporate insiders own 0.27% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Rail Splitter Capital Management LLC boosted its stake in Allergan PLC by 53.8% in the second quarter. Rail Splitter Capital Management LLC now owns 54,169 shares of the company’s stock valued at $12,518,000 after buying an additional 18,945 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Allergan PLC by 12.6% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,402,893 shares of the company’s stock valued at $324,195,000 after buying an additional 156,959 shares during the last quarter. Woodstock Corp boosted its stake in Allergan PLC by 5.3% in the third quarter. Woodstock Corp now owns 32,538 shares of the company’s stock valued at $7,494,000 after buying an additional 1,631 shares during the last quarter. Montag & Caldwell LLC boosted its stake in Allergan PLC by 16.2% in the second quarter. Montag & Caldwell LLC now owns 687,035 shares of the company’s stock valued at $158,767,000 after buying an additional 95,951 shares during the last quarter. Finally, Johnston Asset Management LLC bought a new stake in Allergan PLC during the second quarter valued at $134,170,000. Hedge funds and other institutional investors own 89.21% of the company’s stock.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.